Position in GILD
as of Jun 30, 2026
· filed Jul 16, 2026
Position Value
$10,107
+$8,574 QoQ
Shares Held
80
+627.3% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#2,184
of 2,266 holders
Holding Since
Mar 2020
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GILD Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Davis Capital Management holds $6,297,182 across 10 Drug Manufacturers - General names. GILD ranks #5 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
9,856 | $2,503,128 | |
| 2 | AMGN |
Amgen Inc
|
6,521 | $2,361,384 | |
| 3 | ABBV |
AbbVie Inc.
|
5,302 | $1,334,195 | |
| 4 | LLY |
ELI LILLY & Co
|
61 | $73,165 | |
| 5 | GILD |
Gilead Sciences, Inc.
This page
|
80 | $10,107 | |
| 6 | MRK |
Merck & Co., Inc.
|
58 | $7,453 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
59 | $3,399 | |
| 8 | PFE |
Pfizer Inc
|
137 | $3,298 |
All Filings in GILD
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $10,107 | 80 | Shares | Sole | 2026-07-16 | |
| 2026-03-31 | $1,533 | 11 | Shares | Sole | 2026-04-16 | |
| 2025-12-31 | $1,350 | 11 | Shares | Sole | 2026-01-28 | |
| 2025-09-30 | $888 | 8 | Shares | Sole | 2025-10-21 | |
| 2024-06-30 | $1,921 | 28 | Shares | Sole | 2024-07-02 | |
| 2024-03-31 | $2,051 | 28 | Shares | Sole | 2024-04-05 | |
| 2023-12-31 | $2,268 | 28 | Shares | Sole | 2024-02-14 | |
| 2020-06-30 | $17,311 | 225 | Shares | Sole | 2020-07-29 | |
| 2020-03-31 | $17,718 | 237 | Shares | Sole | 2020-05-13 | |
| No filing history on record for this holder in this stock. | ||||||